124 related articles for article (PubMed ID: 36440989)
1. Small Interfering RNA Delivery Into Primary Human Natural Killer Cells for Functional Gene Analyses.
Momayyezi P; Malmberg KJ; Hammer Q
Curr Protoc; 2022 Nov; 2(11):e613. PubMed ID: 36440989
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of Hypoxia Inducible Factor-1α in Primary Human Natural Killer Cells Using Small Interfering RNA Delivery with ExPERT ATx by MaxCyte.
Velásquez SY; Baslar GE; Schulte J; Fuderer T; Lindner HA; Coulibaly A
Curr Protoc; 2024 Feb; 4(2):e987. PubMed ID: 38327104
[TBL] [Abstract][Full Text] [Related]
3. Ex Vivo Expansion and CRISPR-Cas9 Genome Editing of Primary Human Natural Killer Cells.
Huang RS; Lai MC; Lin S
Curr Protoc; 2021 Sep; 1(9):e246. PubMed ID: 34529358
[TBL] [Abstract][Full Text] [Related]
4. An optimized platform for efficient siRNA delivery into human NK cells.
Palacios D; Momayyezi P; Huhn O; Ask EH; Dunst J; Malmberg KJ; Hammer Q
Eur J Immunol; 2022 Jul; 52(7):1190-1193. PubMed ID: 35416292
[TBL] [Abstract][Full Text] [Related]
5. Electroporation of siRNA to Silence Gene Expression in Primary NK Cells.
Phatarpekar PV; Lee DA; Somanchi SS
Methods Mol Biol; 2016; 1441():267-76. PubMed ID: 27177673
[TBL] [Abstract][Full Text] [Related]
6. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
Matosevic S
J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
[TBL] [Abstract][Full Text] [Related]
7. Cost efficient and effective gene transfer into the human natural killer cell line, NK92.
Grund EM; Muise-Helmericks RC
J Immunol Methods; 2005 Jan; 296(1-2):31-6. PubMed ID: 15680148
[TBL] [Abstract][Full Text] [Related]
8. Transient blockade of TBK1/IKKε allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors.
Chockley P; Patil SL; Gottschalk S
Cytotherapy; 2021 Sep; 23(9):787-792. PubMed ID: 34119434
[TBL] [Abstract][Full Text] [Related]
9. Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation.
Wang X; Lee DA; Wang Y; Wang L; Yao Y; Lin Z; Cheng J; Zhu S
Clin Exp Immunol; 2013 Apr; 172(1):104-12. PubMed ID: 23480190
[TBL] [Abstract][Full Text] [Related]
10. Lipid nanoparticle-mediated messenger RNA delivery for ex vivo engineering of natural killer cells.
Douka S; Brandenburg LE; Casadidio C; Walther J; Garcia BBM; Spanholtz J; Raimo M; Hennink WE; Mastrobattista E; Caiazzo M
J Control Release; 2023 Sep; 361():455-469. PubMed ID: 37567506
[TBL] [Abstract][Full Text] [Related]
11. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
12. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
[TBL] [Abstract][Full Text] [Related]
13. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
[TBL] [Abstract][Full Text] [Related]
14. Feeder-Cell-Free and Serum-Free Expansion of Natural Killer Cells Using Cloudz Microspheres, G-Rex6M, and Human Platelet Lysate.
Johnson CDL; Zale NE; Frary ED; Lomakin JA
Front Immunol; 2022; 13():803380. PubMed ID: 35320938
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo expansion of natural killer cells using cryopreserved irradiated feeder cells.
Baek HJ; Kim JS; Yoon M; Lee JJ; Shin MG; Ryang DW; Kook H; Kim SK; Cho D
Anticancer Res; 2013 May; 33(5):2011-9. PubMed ID: 23645750
[TBL] [Abstract][Full Text] [Related]
16. Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core.
Nakamura T; Yamada K; Fujiwara Y; Sato Y; Harashima H
Mol Pharm; 2018 Jun; 15(6):2142-2150. PubMed ID: 29668291
[TBL] [Abstract][Full Text] [Related]
17. Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self.
Michen S; Frosch J; Füssel M; Schackert G; Momburg F; Temme A
Cytotherapy; 2020 Jul; 22(7):354-368. PubMed ID: 32451262
[TBL] [Abstract][Full Text] [Related]
18. RNA interfering targeting human leukocyte antigen-G enhanced immune surveillance mediated by the natural killer cells on hepatocellular carcinoma.
Zeng XC; Zhang T; Huang DH; Wang GY; Chen W; Li H; Zhang J; Fang TL; Zhang Q; Chen GH
Ann Clin Lab Sci; 2013; 43(2):135-44. PubMed ID: 23694787
[TBL] [Abstract][Full Text] [Related]
19. Modification of Expanded NK Cells with Chimeric Antigen Receptor mRNA for Adoptive Cellular Therapy.
Chu Y; Flower A; Cairo MS
Methods Mol Biol; 2016; 1441():215-30. PubMed ID: 27177669
[TBL] [Abstract][Full Text] [Related]
20. Drug target validation in primary human natural killer cells using CRISPR RNP.
Rautela J; Surgenor E; Huntington ND
J Leukoc Biol; 2020 Oct; 108(4):1397-1408. PubMed ID: 33463756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
